Status:

COMPLETED

Diabetic Retinopathy Candesartan Trials

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Takeda

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

18-50 years

Phase:

PHASE3

Brief Summary

The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopa...

Eligibility Criteria

Inclusion

  • Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included.
  • Duration of diabetes for \> 1 year and \< 15 years with stable diabetic therapy within last 6 months.
  • Patients with untreated resting mean sitting SBP \< 130 mmHg, mean sitting DBP \< 85 mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale).

Exclusion

  • Patients with the following conditions are excluded from participation in the study:
  • Cataract or media opacity of a degree which precludes taking gradable retinal photographs
  • Angle closure glaucoma, which precludes pharmacological dilatation of the pupil
  • History of retinopathy
  • History or presence of clinical significant macular oedema (CSME)
  • History or evidence of photocoagulation of the retina Other retinal conditions which may mask assessment, eg, retinal vein occlusion
  • Positive micral dipstick test
  • Presence of secondary diabetes
  • Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception
  • Need of treatment with ACE-inhibitor
  • Haemodynamically significant aortic or mitral valve stenosis
  • Known renal artery stenosis or kidney transplantation
  • Hypersensitivity to study drug
  • Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator

Key Trial Info

Start Date :

June 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2008

Estimated Enrollment :

5238 Patients enrolled

Trial Details

Trial ID

NCT00252733

Start Date

June 1 2001

End Date

April 1 2008

Last Update

May 14 2014

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Research Site

Herston, Australia

2

Research Site

Perth, Australia

3

Research Site

Odense, Denmark